These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 17049817)
21. [VISA and hetero-VISA among Staphylococcus aureus strains isolated from clinical cases]. Młynarczyk G; Młynarczyk A; Łuczak M Med Dosw Mikrobiol; 2002; 54(1):9-20. PubMed ID: 12185689 [TBL] [Abstract][Full Text] [Related]
22. In vitro activity of omiganan pentahydrochloride tested against vancomycin-tolerant, -intermediate, and -resistant Staphylococcus aureus. Fritsche TR; Rhomberg PR; Sader HS; Jones RN Diagn Microbiol Infect Dis; 2008 Apr; 60(4):399-403. PubMed ID: 18178361 [TBL] [Abstract][Full Text] [Related]
23. Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus. Pillai SK; Wennersten C; Venkataraman L; Eliopoulos GM; Moellering RC; Karchmer AW Clin Infect Dis; 2009 Oct; 49(8):1169-74. PubMed ID: 19769538 [TBL] [Abstract][Full Text] [Related]
24. Correlation of vancomycin and daptomycin susceptibility in Staphylococcus aureus in reference to accessory gene regulator (agr) polymorphism and function. Rose WE; Rybak MJ; Tsuji BT; Kaatz GW; Sakoulas G J Antimicrob Chemother; 2007 Jun; 59(6):1190-3. PubMed ID: 17434881 [TBL] [Abstract][Full Text] [Related]
25. False synergy between vancomycin and beta-lactams against glycopeptide-intermediate Staphylococcus aureus (GISA) caused by inappropriate testing methods. Goldstein FW; Atoui R; Ben Ali A; Nguyen JC; Ly A; Kitzis MD Clin Microbiol Infect; 2004 Apr; 10(4):342-5. PubMed ID: 15059127 [TBL] [Abstract][Full Text] [Related]
26. The activity of daptomycin against wild-type Staphylococcus aureus and strains with reduced susceptibility to vancomycin. Sader HS; Jones RN Clin Infect Dis; 2006 Sep; 43(6):798-9; author reply 799-800. PubMed ID: 16912964 [No Abstract] [Full Text] [Related]
27. Evaluation of accessory gene regulator (agr) group and function in the proclivity towards vancomycin intermediate resistance in Staphylococcus aureus. Tsuji BT; Rybak MJ; Lau KL; Sakoulas G Antimicrob Agents Chemother; 2007 Mar; 51(3):1089-91. PubMed ID: 17158941 [TBL] [Abstract][Full Text] [Related]
28. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Tenover FC; Moellering RC Clin Infect Dis; 2007 May; 44(9):1208-15. PubMed ID: 17407040 [TBL] [Abstract][Full Text] [Related]